BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 20097412)

  • 1. Pure dysgerminoma of the ovary 35 years on: a single institutional experience.
    Vicus D; Beiner ME; Klachook S; Le LW; Laframboise S; Mackay H
    Gynecol Oncol; 2010 Apr; 117(1):23-6. PubMed ID: 20097412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian immature teratoma: treatment and outcome in a single institutional cohort.
    Vicus D; Beiner ME; Clarke B; Klachook S; Le LW; Laframboise S; Mackay H
    Gynecol Oncol; 2011 Oct; 123(1):50-3. PubMed ID: 21764111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ovarian dysgerminoma in children and adolescents. Retrospective clinico-pathologic study].
    Zuntová A; Sumerauer D; Teslík L; Koutecký J
    Cas Lek Cesk; 2004; 143(4):246-52. PubMed ID: 15218724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors.
    Cicin I; Saip P; Guney N; Eralp Y; Ayan I; Kebudi R; Topuz E
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):210-4. PubMed ID: 19419810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pure ovarian dysgerminoma. Evaluation of experiences and definition of a therapeutic strategy].
    Dilhuydy JM; Lagarde P; Chauvergne J; Mongodin B; Dilhuydy MH; Coindre JM; Avril A; Richaud P; Pigneux J
    Bull Cancer; 1990; 77(3):213-24. PubMed ID: 2340352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas.
    Boran N; Tulunay G; Caliskan E; Köse MF; Haberal A
    Arch Gynecol Obstet; 2005 Feb; 271(2):104-8. PubMed ID: 15007601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysgerminoma of the ovary.
    LaPolla JP; Benda J; Vigliotti AP; Anderson B
    Obstet Gynecol; 1987 Jun; 69(6):859-64. PubMed ID: 3574816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysgerminoma: the role of conservative surgery.
    Casey AC; Bhodauria S; Shapter A; Nieberg R; Berek JS; Farias-Eisner R
    Gynecol Oncol; 1996 Dec; 63(3):352-7. PubMed ID: 8946871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
    Suh-Burgmann E
    Gynecol Oncol; 2006 Dec; 103(3):841-7. PubMed ID: 16793124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical analysis of 57 patients with ovarian dysgerminoma].
    Li YF; Li MD; Wu QL; Liu FY; Li JD; Zou JL; Huang YW
    Ai Zheng; 2002 Jan; 21(1):79-82. PubMed ID: 12500404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases.
    Low JJ; Perrin LC; Crandon AJ; Hacker NF
    Cancer; 2000 Jul; 89(2):391-8. PubMed ID: 10918171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
    Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
    Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.
    Dusenbery KE; Bellairs EE; Potish RA; Twiggs LB; Boente MP
    Gynecol Oncol; 2005 Feb; 96(2):307-13. PubMed ID: 15661213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pure dysgerminoma of the ovary: a single institutional experience of 65 patients.
    A L Husaini H; Soudy H; El Din Darwish A; Ahmed M; Eltigani A; A L Mubarak M; Sabaa AA; Edesa W; A L-Tweigeri T; Al-Badawi IA
    Med Oncol; 2012 Dec; 29(4):2944-8. PubMed ID: 22407668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pure dysgerminomas of the ovary. Retrospective analysis of 17 cases treated at the Claudius Regaud Center from 1974 to 1989].
    About I; Bugat R; Naja A; David JF; Mihura J
    Ann Chir; 1993; 47(7):631-40. PubMed ID: 8257049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant ovarian germ cell tumors: a single-institution experience.
    Cicin I; Eralp Y; Saip P; Ayan I; Kebudi R; Iyibozkurt C; Tuzlali S; Gorgun O; Topuz E
    Am J Clin Oncol; 2009 Apr; 32(2):191-6. PubMed ID: 19307952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current therapy for dysgerminoma of the ovary.
    Thomas GM; Dembo AJ; Hacker NF; DePetrillo AD
    Obstet Gynecol; 1987 Aug; 70(2):268-75. PubMed ID: 3299187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.
    Harrison ML; Hoskins P; du Bois A; Quinn M; Rustin GJ; Ledermann JA; Baron-Hay S; Friedlander ML
    Gynecol Oncol; 2006 Feb; 100(2):233-8. PubMed ID: 16321429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome.
    Chan JK; Lin YG; Loizzi V; Ghobriel M; DiSaia PJ; Berman ML
    J Reprod Med; 2003 Oct; 48(10):756-60. PubMed ID: 14619640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.